Verilumia 
FDA advisers back GRAIL’s Galleri test in 7-2 vote
The U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel recommended on September 23 that Galleri, GRAIL’s multicancer blood test, has benefits that outweigh its risks for the proposed screening p...
